NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) resulting from allegations that Akebia Therapeutics may have issued materially misleading business information to the investing public.
Akebia Therapeutics’ lead product candidate is AKB-6548, an oral therapy for the treatment of anemia secondary to chronic kidney disease. On July 24, 2013, Akebia Therapeutics announced it had dosed the first patient in the Phase 2b trial of AKB-6548 for the treatment of anemia associated with chronic kidney disease. On March 20, 2014, Akebia Therapeutics conducted its initial public offering of 5,882,353 shares of common stock at $17.00 per share. On October 27, 2014, Akebia Therapeutics revealed the incidence of serious adverse events in the active treatment group was 8.6% higher that the placebo group in the Phase 2b trial of AKB-6548. On this news, shares of Akebia Therapeutics fell $5.75 per share or over 29% to close at $13.97 per share on October 27, 2014, damaging investors.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Akebia Therapeutics investors. If you purchased shares of Akebia Therapeutics on or before October 26, 2014, please visit the firm’s website at http://rosenlegal.com/cases-737.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.